LFWD — Lifeward Ltd.

Lifeward (LFWD) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $3.9 million, down from $5 million in Q1 2025, primarily due to lower AlterG shipments.
• ReWalk Revenue: Increased 11% year-over-year to $1.6 million, driven by reimbursement coverage and international sales.
• Gross Margin: 34.2%, down from 42.2% in the prior year, attributed to lower manufacturing absorption, higher freight and tariff costs, and unfavorable currency exchange rates.
• Operating Expenses: Total operating expenses rose to $11.7 million, including a one-time R&D expense of $4.9 million related to the Oratech acquisition. Adjusted operating expenses decreased 12% to $5.9 million.
• GAAP Operating Loss: Increased to $10.3 million; adjusted operating loss remained at $4.6 million.
• Cash Position: Ended the quarter with $11.4 million in unrestricted cash, up from $2.2 million at year-end 2025.

2. Strategic Updates and Business Highlights

• Acquisition of Oratech: Completed acquisition to enhance Lifeward's capabilities in neurorehabilitation and gain access to a protein oral delivery platform, including a promising oral insulin product.
• Neurorehabilitation Focus: Continued emphasis on scaling the MedTech business, with progress in distribution and reimbursement for ReWalk.
• New Product Development: Acquired an upper body exoskeleton technology aimed at addressing needs of stroke survivors, with development underway.
• Operational Efficiencies: Improved productivity in sales and marketing, leading to a reduction in adjusted operating expenses.

3. Forward Guidance and Outlook

• Revenue Expectations: Management expects total revenue for 2026 to be similar to 2025, with potential for growth in the latter half of the year as operational issues are resolved.
• Operational Stabilization: Anticipated improvements in shipment execution for AlterG orders in Q2 and Q3, with a backlog of secured orders.
• Long-Term Strategy: Focus on disciplined cash management, operational efficiency, and scalable growth towards profitability.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The year-over-year revenue drop was primarily due to timing issues with AlterG shipments and supply chain disruptions.
• Gross Margin Pressure: Significant decline in gross margin due to tariffs, foreign exchange fluctuations, and reduced production volumes.
• Operational Challenges: Transition to contract manufacturing and facility relocations have caused temporary disruptions and cash constraints.
• Uncertain Market Conditions: Potential risks associated with the integration of new technologies and maintaining competitive positioning in the market.

5. Notable Q&A Insights

• AlterG Shipments: Management indicated that they expect to recover shipment levels in Q2 and Q3, following a backlog of orders.
• Revenue Guidance: Despite lower Q1 figures, management reiterated expectations for 2026 revenue to match 2025 levels, with a positive outlook for the second half of the year.
• Medicare Advantage Coverage: Positive developments in securing coverage with major insurers, with ongoing efforts to expand into traditional Medicare and other private payers.
• Resource Management: CEO Mark Grant emphasized his extensive experience in managing revenue cycles and the strategic approach to partnerships and channel development to enhance market access.

This summary encapsulates the key points from Lifeward's Q1 2026 earnings call, highlighting both the company's progress and the challenges it faces moving forward.